Matthew Isherwood
Clemson University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Matthew Isherwood.
Bioorganic & Medicinal Chemistry Letters | 2010
Zhicai Yang; David J. Fairfax; Jun-Ho Maeng; Liaqat Masih; Alexander Usyatinsky; Carla Hassler; Soshanna Isaacson; Kevin Fitzpatrick; Russell Joseph Deorazio; Jianqing Chen; James P. Harding; Matthew Isherwood; Svetlana Dobritsa; Kevin L. Christensen; Jonathan D. Wierschke; Brian I. Bliss; Lisa H. Peterson; Cathy M. Beer; Christopher L. Cioffi; Michael A. Lynch; W. Martin Rennells; Justin J. Richards; Timothy Rust; Yuri L. Khmelnitsky; Marlene L. Cohen; David D. Manning
A new class of 2-substituted benzoxazole carboxamides are presented as potent functional 5-HT(3) receptor antagonists. The chemical series possesses nanomolar in vitro activity against human 5-HT(3)A receptors. A chemistry optimization program was conducted and identified 2-aminobenzoxazoles as orally active 5-HT(3) receptor antagonists with good metabolic stability. These novel analogues possess drug-like characteristics and have potential utility for the treatment of diseases attributable to improper 5-HT(3) receptor function, especially diarrhea predominant irritable bowel syndrome (IBS-D).
ACS Medicinal Chemistry Letters | 2014
Shuang Liu; Congxiang Zha; Kassoum Nacro; Min Hu; Wenge Cui; Yuh-Lin Yang; Ulhas Bhatt; Aruna Sambandam; Matthew Isherwood; Larry Yet; Michael Herr; Sarah M. Ebeltoft; Carla Hassler; Linda Fleming; Anthony D. Pechulis; Anne Payen-Fornicola; Nicholas Holman; Dennis Milanowski; Ian C. Cotterill; Vadim V. Mozhaev; Yuri L. Khmelnitsky; Peter R. Guzzo; Bruce J. Sargent; Bruce F. Molino; Richard E. Olson; Dalton King; Snjezana Lelas; Yu-Wen Li; Kim A. Johnson; Thaddeus F. Molski
A series of 4-bicyclic heteroaryl 1,2,3,4-tetrahydroisoquinoline inhibitors of the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT) was discovered. The synthesis and structure-activity relationship (SAR) of these triple reuptake inhibitors (TRIs) will be discussed. Compound 10i (AMR-2), a very potent inhibitor of SERT, NET, and DAT, showed efficacy in the rat forced-swim and mouse tail suspension models with minimum effective doses of 0.3 and 1 mg/kg (po), respectively. At efficacious doses in these assays, 10i exhibited substantial occupancy levels at the three transporters in both rat and mouse brain. The study of the metabolism of 10i revealed the formation of a significant active metabolite, compound 13.
Bioorganic & Medicinal Chemistry Letters | 2006
John W. Huffman; Lea W. Padgett; Matthew Isherwood; Jenny L. Wiley; Billy R. Martin
Organic Process Research & Development | 2016
Paul C. Lobben; Rasidul Amin; Bang-Chi Chen; Wenge Cui; Min Hu; Matthew Isherwood; Shuang Liu; Kassoum Nacro; Brandon Miles; Bingidimi I. Mobele; Richard E. Olson; Bei Wang; Yuh-Lin Yang; Rulin Zhao
Archive | 2014
Paul C. Lobben; Zhao Rulin; Wang Bei; Chen Bang-Chi; Shuang Liu; Hu Min; Yang Yuh-Lin Allen; Matthew Isherwood; Rasidul Amin; Cui Wenge
Archive | 2009
Jun Qiu; Qi Gao; Shuang Liu; Min Hu; Yuh-Lin Allen Yang; Matthew Isherwood; Rasidul Amin
Archive | 2009
Paul C. Lobben; Rulin Zhao; Bei Wang; Bang-Chi Chen; Shuang Liu; Min Hu; Yuh-Lin Allen Yang; Matthew Isherwood; Rasidul Amin; Wenge Cui
Archive | 2009
Paul C. Lobben; Rulin Zhao; Bei Wang; Bang-Chi Chen; Shuang Liu; Min Hu; Yuh-Lin Allen Yang; Matthew Isherwood; Rasidul Amin; Wenge Cui
Archive | 2009
Jun Qiu; Qi Gao; Shuang Liu; Min Hu; Yuh-Lin Allen Yang; Matthew Isherwood; Rasidul Amin
Archive | 2006
Bruce F. Molino; Shuang Liu; Aruna Sambandam; Peter R. Guzzo; Min Hu; Congxiang Zha; Kassoum Nacro; David D. Manning; Matthew Isherwood; Kristen N. Fleming; Wenge Cui; Richard E. Olson